There is preclinical evidence that next-generation αC-helix IN RAF inhibitors, and more specifically, the subgroup of RAF dimer selective inhibitors, may provide benefits in targeting BRAF non-V600 mutants (class II and III BRAF mutations) in NSCLC [43]. Here, BRAF is linked to non-small cell lung carcinoma.